What is Roth Capital’s Forecast for MBRX FY2029 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Stock analysts at Roth Capital issued their FY2029 earnings per share estimates for Moleculin Biotech in a research note issued on Thursday, January 9th. Roth Capital analyst J. Aschoff expects that the company will post earnings of $2.81 per share for the year. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

MBRX has been the subject of several other reports. StockNews.com began coverage on Moleculin Biotech in a research note on Wednesday, January 8th. They set a “sell” rating for the company. Maxim Group cut their price target on shares of Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 12th.

Moleculin Biotech Price Performance

Shares of MBRX opened at $1.64 on Monday. Moleculin Biotech has a one year low of $1.50 and a one year high of $11.17. The stock has a 50-day moving average price of $2.27 and a 200 day moving average price of $2.62.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC increased its holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 156,000 shares of the company’s stock after buying an additional 7,505 shares during the period. Armistice Capital LLC owned about 6.75% of Moleculin Biotech worth $549,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.